Malaria: Current status of control, diagnosis, treatment, and a proposed agenda for research and development

Lancet Infectious Diseases

Volumn 2, Issue 9, 2002, Pages 564-573

  Guerin, Philippe J ^a   Olliaro, Piero ^b   Nosten, Francois ^c   Druilhe, Pierre ^d   Laxminarayan, Ramanan ^e   Binka, Fred ^f   Kilama, Wen L ^g   Ford, Nathan ^h   White, Nicholas J ^c,h  

^a EPICENTRE   (France)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

^d INSTITUT PASTEUR   (France)

^e RESOURCES FOR THE FUTURE   (United States)

^f UNIVERSITY OF GHANA   (Ghana)

^g African Malaria Network Trust   (Tanzania)

^h MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

8 AMINOQUINOLINE DERIVATIVE; AMODIAQUINE; ANTIMALARIAL AGENT; ARTELINIC ACID; ARTEMETHER; ARTEMISININ; ARTESUNATE; ATOVAQUONE; BENFLUMETOL; CHLOROQUINE; CHLORPROGUANIL; DAPSONE; DIHYDROARTEMISININ; FOLIC ACID ANTAGONIST; FOSFOMYCIN; MALARIA VACCINE; MEFLOQUINE; PIPERAQUINE; PRIMAQUINE; PYRONARIDINE; QUINOLINE DERIVATIVE; TAFENOQUINE; VACCINE;

ALGORITHM; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; HEALTH CARE POLICY; MALARIA; MALARIA CONTROL; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; VECTOR CONTROL;

EID: 0036724848     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(02)00372-9     Document Type: Note

References (109)

1. The economic and social burden of malaria
2. Malaria, the submerged disease
3. The ears of the hippopotamus: Manifestations, determinants, and estimates of the malaria burden
4. Malaria disaster in Africa
5. The malaria burden and the need for research and capacity strengthening in Africa
6. The public health impact of chloroquine resistance in Africa
7. Delaying antimalarial drug resistance with combination chemotherapy
8. Impact of chloroquine resistance on malaria mortality
9. The economic burden of malaria
10. Evidence-based health policy-lessons from the Global Burden of Disease Study
11. Gaps in the childhood malaria burden in Africa: Cerebral malaria, neurological sequelae, anemia, respiratory distress, hypoglycemia, and complications of pregnancy
12. Impact of Plasmodium falciparum malaria on performance and learning: Review of the evidence
13. The intolerable burden of malaria: A new look at the numbers
14. The burden of malaria in pregnancy in malaria-endemic areas
15. The Gambian National Impregnated Bednet Programme: Costs, consequences and net cost-effectiveness
16. Efficacy and cost-effectiveness of environmental management for malaria control
17. Immunity to liver stages
18. Insecticide-treated materials for malaria control in Latin America: To use or not to use?
19. Progress and challenges for malaria vaccines
20. Clinical trials of malaria vaccines: Progress and prospects
21. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites
22. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers
23. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria
24. Using DNA-based vacccine technology and the Malaria Genome Project to overcome obstacles to malaria vaccine development
25. Malaria transmission-blocking vaccines: How can their development be supported?
26. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria
27. An efficacy trial of the malaria vaccine SPf66 in Gambian infants: Second year of follow-up
28. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand
29. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria
30. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: A randomised trial
31. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers
32. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea
33. Phase trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid
34. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3
35. Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys
36. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection
37. Human malaria in immunocompromised mice: An in vivo model to study defense mechanisms against Plasmodium falciparum
38. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys
39. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
40. Malaria vaccines: Are seven antigens better than one?
41. Clinical features cannot predict a diagnosis of malaria or differentiate the infecting species in children living in an area of low transmission
42. Risk factors for anemia in young children in rural Malawi
43. Fever in Africa: Do patients know when they are hot?
44. The epidemiology of malaria
45. Presumptive diagnosis of malaria results in a significant risk of mistreatment of children in urban Sahel
46. Clinical algorithm for treatment of Plasmodium falciparam malaria in children
47. Clinical diagnosis of malaria on the Thai-Myanmar border
48. Malaria diagnosis and treatment under the strategy of the integrated management of childhood illness (IMCI): Relevance of laboratory support from the rapid immunochromatographic tests of ICT Malaria P.f/P.v and OptiMal
49. Clinical diagnosis of uncomplicated malaria in Sri Lanka
50. Changing the first line drug for malaria treatment: Cost-effectiveness analysis with highly uncertain inter-temporal trade-offs
51. The diagnosis of Plasmodium falciparum infection in Gambian children, by field staff using the rapid, manual, ParaSight-F test
52. Comparison of a parasite lactate dehydrogenase-based immunochromatographic antigen detection assay (OptiMAL) with microscopy for the detection of malaria parasites in human blood samples
53. Paracheck-Pf: A new, inexpensive and reliable rapid test for P falciparum malaria
54. MalaQuick versus ParaSight F as a diagnostic aid in travellers' malaria
55. Diagnostic performance of two antigen capture tests for the diagnosis of Plasmodium falciparum malaria in Zimbabwe
56. WHO Informal Consultation on Recent Advances in Diagnostic Techniques and Vaccines for Malaria. A rapid dipstick antigen capture assay for the diagnosis of falciparum malaria
57. Non-microscopic methods for diagnosis of malaria
58. Cost-effectiveness of malaria control in sub-Saharan Africa
59. Global malaria control
60. Implementation of the global malaria control strategy
61. Impact of large-scale rectal artesunate deployment in the emergency management of malaria
62. Intrarectal administration of quinine: An early treatment for severe malaria in children?
63. Uganda leads the way on Africa Malaria Day
64. Making malaria-treatment policy in the face of drug resistance
65. Modelling a predictable disaster: The rise and spread of drug-resistant malaria
66. Antimalarial drug resistance and combination chemotherapy
67. Fake antimalaria drugs in Cambodia
68. Fake artesunate in southeast Asia
69. Antimalarial drug resistance and mortality in falciparum malaria
70. Beyond chloroquine: Implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa
71. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: What next?
72. Mode of action and mechanisms of resistance for antimalarial drugs
73. Modern chemotherapeutic options for malaria
74. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae
75. Combination therapy for malaria
76. Averting a malaria disaster
77. A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria
78. Severe falciparum malaria
79. The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria
80. Dexamethasone deleterious in cerebral malaria
81. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: A randomised, controlled intervention study
82. A study of the consequences of malarial infection in pregnant women and their infants
83. An assessment of low birthweight risk in primiparae as an indicator of malaria control in pregnancy
84. Malaria and pregnancy: Epidemiology, pathophysiology and control options
85. Artemisinin derivatives in the treatment of falciparum malaria in pregnancy
86. Randomized trial of artesunate and mefloquine in comparison with quinine sulfate to treat P. falciparum malaria in pregnant women
87. The neglected burden of Plasmodium vivax malaria
88. Drug resistant falciparum malaria: Clinical consequences and strategies for prevention
89. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: A prospective study
90. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: A randomised, multicentre trial
91. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: A double-blind, randomised, controlled trial
92. DNA microarrays for malaria
93. The impact of whole genome sequence data on drug discovery - A malaria case study
94. Malaria in 2002
95. Malaria: New developments in treatment and prevention
96. Drug development output from 1975 to 1996: What proportion for tropical diseases?
97. Drug development for neglected diseases: A deficient market and a public-health policy failure
98. The HIV/AIDS pandemic: A sign of instability in a complex global system